140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

Autor: Daud, A., Hamid, O., Robert, C., Hodi, F.S., Wolchok, J.D., Hwu, W.J., Weber, J.S., Kefford, R., Hersey, P., Joshua, A.M., Joseph, R., Gangadhar, T.C., Dronca, R., Patnaik, A., Zarour, H., Gerigich, K., Lunceford, J., Emancipator, K., Dolled-Filhart, M., Li, X., Kang, P., Ebbinghaus, S., Ribas, A.
Zdroj: In European Journal of Cancer November 2014 50 Supplement 6:48-49
Databáze: ScienceDirect
Externí odkaz: